Tag:
Pozen
Latest Headlines
Latest Headlines
Pozen shares jump on promising outcome for PhIII studies
Pozen's stock surged 19% after it announced positive data for its amped-up aspirin.
FDA won't extend exclusivity on GSK-marketed drug
Pozen said FDA will not grant a pediatric exclusivity to its Treximet migraine drug, a decision that can open up generic competition. Marketed by Pozen's U.S. partner GlaxoSmithKline, Treximet's
Pozen poised for profits after Vimovo wins approval
Shares of Pozen shot up 21 percent on Friday after the FDA sanctioned its new combo therapy for arthritis. Vimovo, developed in partnership with AstraZeneca, contains the NSAID pain drug naproxen
Pozen's shares soar as FDA approves study results
Chapel Hill, NC-based Pozen saw its stock soar Thursday on the news that the FDA accepted its primary endpoint for two late-stage clinical trials PN 400, its arthritis drug. PN 400, which is being
Pozen touts positive data on new arthritis therapy
Pozen has taken another step toward the regulatory approval of a new arthritis treatment. The Chapel Hill, NC biotech says that PN 400--which is partnered with AstraZeneca--produced new data
ALSO NOTED: Acadia reports positive psychosis data; Alcon drug gets approval; FDA green lights migraine drug; and much more...
> Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS
GSK rebuked for missing Avandia reports
GlaxoSmithKline got a trip to the FDA woodshed for failing to regularly report post-marketing data it was gathering on the diabetes med Avandia. GSK failed to include updates on as many as 18
AstraZeneca, Pozen start Phase III combo drug trial
AstraZeneca and Pozen are starting Phase III trial of PN400, an experimental drug for arthritis pain that combines AstraZeneca's heartburn drug Nexium with the anti-inflammatory drug naproxen. In
Pozen shares sink on latest Trexima delay
Pozen stock took a painful dive this morning after GlaxoSmithKline announced that their two-in-one migraine drug Trexima would be delayed yet again--this time to satisfy FDA demands for more
ALSO NOTED: FDA deadline looms for Trexima; Manhattan Pharma discontinues program; and much more...
> An August 1 FDA action date for Pozen's migraine drug Trexima is looming, and the analysts are paying close attention as the decision deadline nears. Report
> Manhattan Pharmaceuticals says it will …
